{"id":"eviplera","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Abnormal liver function tests"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":{"chemblId":"CHEMBL175691","moleculeType":"Small molecule","molecularWeight":"366.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eviplera combines rilpivirine (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor). Together, these agents target different steps of HIV replication, preventing the virus from converting its RNA genome into DNA and integrating into host cells, thereby reducing viral load and slowing disease progression.","oneSentence":"Eviplera is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:24.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve adults with viral load ≤100,000 copies/mL"}]},"trialDetails":[{"nctId":"NCT02345252","phase":"PHASE3","title":"Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":632},{"nctId":"NCT02529059","phase":"PHASE4","title":"SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-11","conditions":"HIV","enrollment":40},{"nctId":"NCT02547844","phase":"PHASE4","title":"Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-09","conditions":"HIV-1","enrollment":30},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT02196064","phase":"","title":"Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the \"The HEPAVIR HEPATIC SAFETY Cohort.\"","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2014-05","conditions":"Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Coinfected Subjects","enrollment":519},{"nctId":"NCT01309243","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-02","conditions":"HIV-1 Infection","enrollment":799},{"nctId":"NCT01796431","phase":"PHASE1","title":"Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2013-03","conditions":"HIV","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["emtricitabine/rilpivirine/tenofovir","Rilpivirine, tenofovir, emtricitabine"],"phase":"marketed","status":"active","brandName":"Eviplera®","genericName":"Eviplera®","companyName":"St Stephens Aids Trust","companyId":"st-stephens-aids-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eviplera is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes. Used for HIV-1 infection in treatment-naïve adults with viral load ≤100,000 copies/mL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}